Company intelligence / Profile preview

KL Midori

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Midori Bio was a biotechnology company focused on developing a novel platform for the targeted modulation of the microbiome. The company's technology aimed to influence the microbial community in the gut to improve health outcomes, primarily focusing on animal health and enteric diseases. By utilizing specific glycans and small molecules, Midori sought to promote the growth of beneficial bacteria while inhibiting pathogens. The company was eventually acquired by DSM (now dsm-firmenich) to bolster their gut health and animal nutrition portfolio.

Therapeutic areas: OtherGastroenterology
Modalities: Microbial therapySmall molecule
Industry: Veterinary

Partnerships

DSM

Beyond the preview

Go deeper on KL Midori.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL Midori.

Explore the full profile